Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

BMI shouldn’t be the only way to assess who can access weight-loss drugs

Around one in three Australian adults (32%) has a body-mass index (BMI) of 30 or above. A further 34% has a BMI of 25 or above.

The Conversation · Oct 13, 2025

Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations

Bill Gates and the Pan American Health Organization (PAHO) are reportedly developing plans to expand access to popular weight-loss drugs such as Novo Nordisk A/S’ (NYSE:NVO) Wegovy and Eli Lilly and Co.’s (NYSE:LLY) Mounjaro in low- and middle-income countries.

Benzinga · Oct 10, 2025

Weight loss drug stigma shows society still holds negative attitudes towards body weight and obesity

Since Wegovy received approval as a weight loss treatment in 2021, there has been huge demand for GLP-1 drugs. These drugs reduce hunger and suppress the “food noise” that can make it difficult to lose weight.

The Conversation · Oct 9, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

‘They’ve come for the hot chocolate’: More refills banned due to new government obesity laws

People have hit out at the policy that will restrict customers to one mug of hot chocolate at Morrisons supermarkets

The Independent UK · Oct 9, 2025

Calorie labelling rules on menus don’t prompt restaurants to make healthy changes, study finds

The findings deal the latest blow to England’s calorie labelling rules.

Euronews · Oct 8, 2025

Nando's Bans Bottomless Coke as Sugar Crackdown Intensifies — But How Obese Has Britain Really Become?

Nando's ends bottomless Coke refills as part of the UK's sugar crackdown — reflecting a nation where 1 in 4 adults now live with obesity.

International Business Times UK · Oct 7, 2025

Nando’s customers now restricted to just one Coca-Cola Classic under new government rules

Regulations aimed at tackling sugar consumption and obesity hit diners at the popular chicken chain

The Independent UK · Oct 6, 2025

Read news from The Economist, FT, and more,
with one subscription

Childhood Obesity: How Parents Can Help Their Kids Who Are Overweight

Learn how to help your child who is experiencing being overweight and avoid getting into obesity.

International Business Times · Oct 4, 2025

‘Buy one get one free’ junk food deals banned from today

New restriction will also be followed by a ban on junk food advertising on TV before 9pm from January

The Independent UK · Oct 1, 2025

Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial

Metsera, Inc. (NASDAQ:MTSR) on Tuesday released topline data from VESPER-1 and data from a planned interim analysis for tolerability of VESPER-3 – two Phase 2b trials of MET-097i with potential for monthly dosing.

Benzinga · Sep 30, 2025

Researchers sound alarm on junk food addiction that is affecting 1 in 5 young women today

An ultraprocessed diet has been linked to rising obesity rates in America, as well as an increased risk of heart disease, cancer and premature death

The Independent UK · Sep 29, 2025

Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?

As the battle for dominance heats up in the weight loss market, which stock is a better investment now?

Barchart · Sep 29, 2025

Children to see fewer ads for unhealthy food and drink from this week

The move to tackle childhood obesity will stop ads for ‘less healthy’ food and drink appearing on TV between 5.30am and 9pm, and online at any time.

Evening Standard · Sep 29, 2025

US refuses to back UN declaration on noncommunicable diseases

General assembly backs new targets on cancer, diabetes and heart disease but Robert F Kennedy Jr objects

The Guardian - UK · Sep 26, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Sep 25, 2025

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move?

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The termination is a setback for Lilly’s obesity pipeline among growing investor expectations.

Tom’s Guide · Sep 25, 2025

The clocks are falling back early this year, but new study reveals Daylight Saving Time harms our health — here’s why

Scientists reveal the true harm Daylight Saving Time has on our health and sleep

Benzinga · Sep 25, 2025

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch

On Wednesday, Eli Lilly Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

LiveScience · Sep 24, 2025

Abandoning daylight saving time could prevent over 300,000 stroke cases a year in the US, study claims

Springing forward by an hour each March knocks the circadian rhythm out of alignment. A new model of the chronic health impacts argues for scrapping it entirely.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Sep 22, 2025

Roche Targets Top Spot In Weight Loss Drug Market

Roche Holdings AG (OTC:RHHBY) on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO).

International Business Times UK · Sep 22, 2025

Metsera Stock Rockets After Pfizer's $7.3b — Should You Still Invest?

Metsera stock has soared after Pfizer announced a $7.3 billion acquisition, sparking investor buzz. Analysts are now weighing whether the biotech rally has more room to run or if buyers should stay cautious.

Euronews · Sep 22, 2025

Pfizer eyes obesity drug market as it seals $4.9bn deal for Metsera

Pharma giant Pfizer is betting on obesity treatments as it looks for new markets following the success of its COVID-19 vaccine.

Benzinga · Sep 22, 2025

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases.

The Independent UK · Sep 22, 2025

Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera

Benzinga · Sep 22, 2025

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market

Pfizer Inc. (NYSE:PFE) stock climbed 1.54% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ:MTSR), a developer of anti-obesity drugs.

Benzinga · Sep 19, 2025

Could This New Drug Be The Safer Way To Fight Obesity?

On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting.

1 … 22 23 24 25

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.